Business Wire

DIC, Debut Biotech Team Up to Develop and Bio-Manufacture Natural Pigments for More Sustainable Food Colorants and Cosmetics

Share

DIC Corporation (TOKYO:4631) announced a joint research development agreement with California-based biotech startup Debut Biotechnology, Inc., further enhancing DIC efforts to develop natural pigments for food colorants and cosmetics.

In recent years, increasingly urgent climate concerns have increased global consumer demand for biodegradable, naturally derived colorants—notably in foods and cosmetics—to replace synthetic petroleum-derived colorants. This rapidly increasing consumer demand has motivated major global brands to seek out more sustainable materials for their products.

Unfortunately, the increasing efforts to extract useful pigments from natural materials, including flowers or plants, continue to face significant commercialization challenges, including unacceptably low yields, excessive post-extraction waste generation, and environmental burdens, such as land and water use. Moreover, problems specific to agriculture, such as increasingly unstable weather as well as qualitative and quantitative fluctuations remain as barriers to efficient production.

While more organizations are now researching ways to efficiently culture bacteria, yeast, or algae, etc., using biological reactions within cells to produce needed materials, the by-products generated by these reactions continue to foil attempts to conduct reaction processes under optimum conditions.

Debut’s proprietary next-generation continuous cell-free biomanufacturing technology overcomes these traditional biomanufacturing barriers—retaining enzymes and other useful parts of cells, while discarding limiting parts. By working with vital cell enzymes and such under optimum conditions, Debut Biotech engineers optimize reactions, synthesizing stable targets with high purity to efficiently and continuously manufacture biomaterials and other active ingredients previously overlooked due to low material yields.

Debut, CEO Joshua Britton said, “With our advanced cell-free biomanufacturing platform, we’re able to produce color ingredients that are simply not possible with traditional fermentation-based biomanufacturing. Our colors are naturally-derived with a fraction of the inputs—less waste and energy—and without the use of petrochemicals. With this approach, we’re able to take on a level of complexity that creates whole new possibilities for the color ingredient landscape across industries. We’re thrilled to be working with DIC as they’re established leaders in the color ingredients industry.”

DIC Managing Executive Officer Kiyofumi Takano said, “DIC hopes to combine Debut's advanced knowledge of enzyme reactions and process design with DIC’s scale-up technology, quality control, and product development capabilities to develop and commercialize new sustainable, high value-added bio-based colorants, pigments, and healthy foods for global markets.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

DIC Corporation
Keisuke Miyake
+81(3)6733-3033
keisuke-miyake@ma.dic.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*21.9.2021 14:45:00 EEST | Press release

PRESCRIBING INFORMATION IS AVAILABLE AT THE END OF THIS RELEASE FOR MEDICAL BUSINESS / HEALTHCARE INDUSTRY TRADE MEDIA ONLY Theramex has today launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. Bijuva®, (known as Bijuve® in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule.1,2 Unlike synthetic hormone products, the estradiol and progesterone found in Bijuva® / Bijuve® are chemically and biologically identical to the hormones naturally circulating in the woman’s body.3 Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑identical hormones is associated with lower risks compared to synthetic versions. 4,5 In particular, the evidence base demonstrates that body-identical hormones have

Hologic Releases Results of Inaugural Global Women’s Health Index – First Study Representing the Health of 2.5 Billion Women and Girls21.9.2021 14:00:00 EEST | Press release

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index, the world’s most comprehensive, globally comparative survey about women’s health. Developed in partnership with leading analytics and advice firm Gallup, the Hologic Global Women’s Health Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time. Its findings are based on the experiences of more than 60,000 women and girls from 116 countries and territories, captured in more than 140 languages. Conducted as part of the Gallup World Poll, which began in 2005, the Hologic Global Women’s Health Index represents the feelings and actions of approximately 2.5 billion women and girls. Based on responses from the 120,000 total individuals surveyed, women’s health needs are not being met globally. The global score was 54 out of 100 on the Index, and no one country or territory scor

CBRE GLOBAL INVESTORS JULKAISEE EUROPEAN RESIDENTIAL IMPACT FUNDIN NELJÄN SIJOITTAJAN TEKEMÄLLÄ 465 MILJOONAN EURON PÄÄOMASITOUMUKSELLA21.9.2021 13:52:00 EEST | Tiedote

Tämä on markkinointiviesti. Tutustu CBRE European Residential Impact Fund S.C.A. SICAV-SIFin perustamiskirjaan ennen lopullisten sijoituspäätösten tekemistä. Tämän julkaisun kautta ei tehdä tarjousta yhdysvaltalaisille sijoittajille. Tämä julkaisu ei muodosta tarjousta myydä tai ostaa CBRE European Residential Impact Fund S.C.A. SICAV-SIFin osakkeita tai mitään muuta tuotetta, eivätkä yhdysvaltalaiset sijoittajat voi käyttää sitä tai tukeutua siihen tehdessään sijoituspäätöksiä. Kaikki tarjoukset tehdään vain luottamuksellisen perustamiskirjan ja siihen liittyvän tilaussopimuksen kautta, jotka toimitetaan vain päteville sijoittajille. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20210921005579/fi/ Paul Oremus, CBRE European Residential Impact Fundin rahastonhoitaja (Photo: Business Wire) CBRE Global Investors, joka on yksi maailman johtavia kiinteän omaisuuden hoitoyhtiöitä, ilmoittaa tänään CBRE European Residential Impa

FourKites Names 60+ Customers as Innovation Partners to Accelerate Supply Chain Innovation and Increase Business Value21.9.2021 13:49:00 EEST | Press release

FourKites®, the world’s leading real-time supply chain visibility platform, today welcomed more than 60 customers into its formal Innovation Partner program, designed to accelerate customer-driven innovation and shape the future of digital supply chains. The first formal cohort of Innovation Partners includes Henkel, AB InBev, Cardinal Health, Ecolab, Kimberly-Clark, Meijer, Smithfield, Canadian Forest Products and Andersen Corporation, among others. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005575/en/ FourKites® today welcomed more than 60 customers into its formal Innovation Partner program, designed to accelerate customer-driven innovation and shape the future of digital supply chains. (Graphic: Business Wire) FourKites’ leading community of global shippers, freight forwarders and 3PLs have long been active contributors and co-innovators in FourKites’ solutions and product roadmap. The establishment of the Inno

Cybercriminal Attacks Accelerate Global Cybersecurity Crisis According to 1H2021 NETSCOUT Threat Intelligence Report21.9.2021 13:00:00 EEST | Press release

NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report that underscore the dramatic impact cyberattacks continue to have on private and public organizations and governments worldwide. In the first half of 2021, cybercriminals launched approximately 5.4 million Distributed Denial of Services (DDoS) attacks, increasing 11% over 1H2020 figures. Additionally, data projections from NETSCOUT's Active Level Threat Analysis System (ATLAS™) Security Engineering and Response Team (ASERT) point to 2021 as another record-setting year on track to surpass 11 million global DDoS attacks. ASERT expects this long tail of attacker innovation to last, fueling a growing cybersecurity crisis that will continue to impact public and private organizations. In the wake of Colonial Pipeline, JBS, Harris Federation, Australian broadcaster Channel Nine, CNA Financial, and several other high-profile attacks, the impact of DDoS and other cybersecurity attacks h

Clinical Investigation Shows Herb-Pharma's ViroStop Spray Effective in Reducing Impact of Covid-1921.9.2021 13:00:00 EEST | Press release

A recent clinical study has shown that the ViroStop anti-viral spray from Swiss company, Herb-Pharma is effective in reducing the impact of Covid-19 for patients with mild to moderate symptoms. The key benefits were a 60% reduction in viral shedding after using the treatment and a reduction in the severity of clinical respiratory symptoms. The study supports the findings of earlier in-vitro tests where its mix of polyphenols inhibited the growth of the virus in cell cultures. The study included 170 PCR confirmed SARS-CoV-2 patients at the Complex Medical Clinic in Budapest, Hungary between January 15th, and May 31st, 2021. The volunteers all had mild to moderate respiratory symptoms, having tested positive in PCR tests for Covid-19 at the start of the study, and their symptoms were monitored over 12 days. Of the 170 volunteers, 86 received a nasopharyngeal spray, the patented ViroStop solution, which contains a mixture of Cistus Creticus and other polyphenol-rich ingredients. Polypheno

Biedermann Motech To Further Expand MOSS VRS® - The Next Generation Pedicle Screw Technology™ By Adding MOSS Modularity™21.9.2021 13:00:00 EEST | Press release

Biedermann Motech, the company that developed the world’s first polyaxial pedicle screw (MOSS® System) and pioneer in the spinal market for more than 35 years, today announced that its MOSS VRS® Pedicle Screw Platform, the most advanced system on the market today, is now available as a fully modular solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005274/en/ The Next Generation: MOSS VRS®. Real-Time Intraoperative Decision Making. (Graphic: Business Wire) The MOSS VRS System features Next Generation Pedicle Screw Technology™, which allows the surgeon to lock the polyaxial angle of the pedicle screw at any angle, at any time during surgery. This provides surgeons unmatched intraoperative real-time options using a single, highly functional implant. In contrast to traditional pedicle screw systems, which include a wide range of different screw types, the MOSS VRS Pedicle Screw can be locked and unlocked as and whe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom